Who is sponsoring NCT05327322?

NCT05327322 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT05327322?

Interventions in NCT05327322: Glycemic load, Calorie restriction, Behavioral support.

What condition does NCT05327322 study?

NCT05327322 studies Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis.

Is NCT05327322 still recruiting?

NCT05327322 is currently active, enrolled. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT05327322: FOOD_for_MS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Functional Outcomes From Diets in Multiple Sclerosis

Active, enrolled NA Last updated 3 April 2026

What this trial tests

NA trial testing Glycemic load in Relapsing Remitting Multiple Sclerosis in 100 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

20 March 2023

Primary endpoint
1 November 2026

1 November 2026

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	100
Start date	20 March 2023
Primary completion	1 November 2026
Estimated completion	1 November 2026
Sites	2 locations across United States

Drugs / interventions tested

Glycemic load
Calorie restriction
Behavioral support

Conditions studied

Relapsing Remitting Multiple Sclerosis — all drugs for Relapsing Remitting Multiple Sclerosis →
Secondary Progressive Multiple Sclerosis — all drugs for Secondary Progressive Multiple Sclerosis →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 18 to 65, any sex, with Relapsing Remitting Multiple Sclerosis or Secondary Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the effects of two dietary interventions, glycemic load and calorie restriction, on physical function, cognition, pain, fatigue, mood, and anxiety in adults with multiple sclerosis (MS). The investigators will also explore the how the diet interventions impact inflammation, immunity, and metabolic biomarkers.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Immunosenescence in aging and neurodegenerative diseases: evidence, key hallmarks, and therapeutic implications.
Chen Z, Mao Z, Tang W, Shi Y, et al · · 2025 · cited 4× · PMID 41299782 · DOI 10.1186/s40035-025-00517-1
Leptin and Leptin Signaling in Multiple Sclerosis: A Narrative Review.
Flores-Cordero JA, Aranaz-Murillo A, Vilariño-García T, Pérez-Pérez A, et al · · 2025 · cited 4× · PMID 40019662 · DOI 10.1007/s12017-025-08842-4
Functional outcomes of diets in multiple sclerosis (FOOD for MS): Protocol for a parallel arm randomized feeding trial for low glycemic load and calorie restriction.
Martin K, Cofield SS, Cross AH, Goss AM, et al · · 2024 · cited 2× · PMID 38821260 · DOI 10.1016/j.cct.2024.107584

Verify or expand the search:

Other recruiting trials for Relapsing Remitting Multiple Sclerosis

Currently open trials in the same condition.

NCT06796504 — The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study · NA · recruiting
NCT05949580 — Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple · recruiting
NCT06282081 — Serum Neurofilament Light in Multiple Sclerosis · active not recruiting
NCT05171972 — Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment · active not recruiting
NCT04688788 — Non-inferiority Study of Ocrelizumab and Rituximab in Active Multiple Sclerosis · Phase 3 · active not recruiting

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05327322 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05327322.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing